Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.

Wassmann, B

Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. [electronic resource] - Bone marrow transplantation Oct 2001 - 721-4 p. digital

Publication Type: Case Reports; Journal Article

0268-3369

10.1038/sj.bmt.1703222 doi


Antineoplastic Agents--adverse effects
Antineoplastic Agents, Alkylating--therapeutic use
Benzamides
Bone Marrow Transplantation--adverse effects
Colitis--chemically induced
Combined Modality Therapy
Enzyme Inhibitors--adverse effects
Female
Graft Survival
Graft vs Host Disease--etiology
Graft vs Leukemia Effect
Hematopoietic Stem Cell Transplantation
Humans
Hydroxyurea--therapeutic use
Imatinib Mesylate
Immunosuppression Therapy
Interferon-alpha--therapeutic use
Leukemia, Myeloid, Accelerated Phase--drug therapy
Leukemia, Myeloid, Chronic-Phase--drug therapy
Lymphocyte Transfusion
Middle Aged
Neoplasm Recurrence, Local--drug therapy
Neoplasm, Residual
Neutropenia--chemically induced
Piperazines--adverse effects
Pyrimidines--adverse effects
Remission Induction
Salvage Therapy
Transplantation Conditioning
Transplantation, Homologous